Michele Hooper

Michele Hooper is a seasoned professional in the field of drug safety and molecular biology, currently serving on the Scientific Advisory Board at Xylome Corporation since May 2021, focusing on sustainable product development. Prior experience includes holding the position of Vice President of Safety and Pharmacovigilance at Kite Pharma from October 2017 to April 2021, and providing consulting services in Patient Safety, Pharmacovigilance, and Risk Management as a consultant from November 2014 to September 2017, with a notable achievement in successfully leading an Advisory Committee meeting for Siliq (TM) in July 2016. Earlier roles at Amgen from February 2006 to October 2014 included serving as Executive Medical Director and Therapeutic Area Head for Inflammation Safety, as well as Medical Director overseeing the development of Enbrel. Michele Hooper holds a Doctor of Medicine (MD) from McGill University and a Masters in Research Design and Statistics from the University of Michigan.